Uncurtaining the impact of COVID-19 in diabetes mellitus: a fancy medical administration strategy


This article was originally published here

Environ Sci Pollut Res Int. 2021 May 21st doi: 10.1007 / s11356-021-14480-7. Online before printing.


The aim of this overview is to give an overview of the common properties of the coronavirus and thus to prove the onset of the coronavirus in people with diabetes and its treatment. Globally, it has been observed that India has the second largest number of people with diabetes according to statistics. The literature search was implemented in the databases using suitable keywords. For people with diabetic disorder, COVID-19 infection becomes a double challenge. Diabetes is a difficult metabolic situation in which the level of sugar in the blood rises above normal. Typically, a communicable disease like COVID-19 is more common in people with diabetes. Diabetics have a poor immune response to infections. The various bacterial, viral, parasitic and mycotic infections showed an increased likelihood in diabetics compared to non-diabetics. All of these conclusions illustrate the intent that diabetics are more prone to an increased inflammatory response, which can lead to the rapid spread of COVID-19 infection with high mortality rates. In the current pandemic situation, treating diabetes seems quite challenging and diabetics with COVID-19 infection should follow the normal course of prescribed antihypertensive and anti-diabetic drugs other than sodium glucose co-transpotent-2 inhibitors, which would increase the risk of dehydration and ketoacidosis. In light of the discussion above, this article highlights the proposed mechanism of COVID-19 infection linking it to diabetes, antidiabetic drugs to be used in COVID-19 infection, their advantages and disadvantages, and how to manage COVID 19 infectious diabetics.

PMID: 34021454 | DOI: 10.1007 / s11356-021-14480-7